This method is for producing a transition metal complex represented by formula (2), the method comprising reacting a compound containing a transition metal selected from V, Cr, Mo, W, Fe, Ru, Co, Rh, Ni, Pd, and Pt with an isocyanide compound represented by formula (1) in the presence of an alkali metal supported by a solid substance which is insoluble in an organic solvent. This production method can be used to easily and efficiently produce a transition metal complex that includes a predetermined transition metal having an oxidation number of 0 and that has the same or different isocyanide compounds, without using a compound harmful to the human body. (1): (CN).sub.xR.sup.1 {R.sup.1 represents a mono- to tri-valent organic group having 1-30 carbon atoms, and x represents an integer of 1-3}. (2): M.sup.1.sub.a(L).sub.b {M.sup.1 represents V, Cr, Mo, W, Fe, Ru, Co, Rh, Ni, Pd, or Pt, and is a zero-valent transition metal, L represents an isocyanide compound represented by formula (1), M.sup.1 and L may be the same or different from each other, a represents an integer of 1-8, and b represents an integer of 2-12}.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 M. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 M.

Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 M. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 M.

A compound represented by Formula (1), Formula (2), or Formula (3), or a salt thereof, or a solvate thereof:

##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are the same or different and each represent a hydrazine group, an N-hydroxy-acetylamino group, or an N-hydroxy-formylamino group.